Singapore markets open in 6 hours 27 minutes

Straits Times Index
3,296.89
+4.20(+0.13%)
S&P 500
5,061.64
+43.25(+0.86%)
Dow
38,212.92
+309.63(+0.82%)
Nasdaq
15,823.44
+217.96(+1.40%)
Bitcoin USD
59,074.46
+1,162.11(+2.01%)
CMC Crypto 200
1,276.10
+5.36(+0.42%)

Alzamend Neuro, Inc. (ALZN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

0.7010

-0.0390

(-5.27%)

As of 01:58PM EDT. Market open.

Trade prices are not sourced from all markets

All

Insider Monkey
Insiders Are Buying These 11 Penny Stocks
In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024 in the red, driven by rising treasury yields, broader volatility and uncertainty around rate cuts […]
Benzinga
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year
Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD). "Although lithium does not have an FDA-approved indication for PTSD, it has been prescribed off-label for this purpose for decades," said Stephan Jackman, Chief Executive Officer of Alzamend. "If we can develop a next-generation lithium product (AL001) that would not routinely require therapeutic drug m
Business Wire
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
ATLANTA, December 11, 2023--Alzamend Neuro Receives FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug to Treat PTSD